Why Allergan Continues to Slide
Though Allergan reported better than expected quarterly results before the markets opened on Tuesday, its shares retreated.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 145
Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors
Fourth-quarter and full-year earnings at Bristol-Myers Squibb beat estimates, but a report of the successful trial of the company's lung cancer treatment may be the big mover for the stock Monday.
Major Biopharma Catalysts on February’s FDA Calendar
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Evolus Gears Up for IPO
Medical aesthetics company Evolus expects to price 5.0 million shares in a range that results in an initial public offering valued up to more than $80 million.
Merck Sees Big Boost From Keytruda in Q4
Merck reported mixed fourth-quarter financial results before the markets opened on Friday.
Why Cascadian Therapeutics Shares Are Skyrocketing
Cascadian Therapeutics saw its shares absolutely skyrocket on Wednesday after it was announced that Seattle Genetics would be acquiring the company. This is far and away the top-performing stock in Wednesday’s session.
Eli Lilly Cruises Through Q4 Earnings
Eli Lilly reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Amazon, Berkshire, JPMorgan Combine to Lower Health Care Costs
Three of America's best-known companies are creating an independent company with the goal to reducing costs and improving healthcare services for their employees. Health insurers are taking a hit to their stock prices.
Pfizer Earnings, Guidance May Not Be Enough for Investors
Pharmaceuticals giant Pfizer beat quarterly and full-year expectations this morning, but the beats were small and the forecast for next year is not exhilarating.
Can Zynerba Pharma Shares Really Still Double in These High Times?
While Zynerba's share price is still roughly half of last year's peak, the company has gotten attention from Wall Street with big upside in analyst calls in recent days.
6 Speculative Biotech Stocks With 50% to 250% Potential Upside
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
Top Stocks to Look For in February’s FDA Calendar
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
AbbVie’s Q4 Boosted by Strong Segment Results
AbbVie reported better-than-expected fourth-quarter financial results before the markets opened on Friday.
Why Analysts Keep Chasing Abbott Labs Higher and Higher
24/7 Wall St. has noticed that analysts and investors seem to not be able to get enough of Abbott Laboratories.
Major Pharma Short Interest Keeps Climbing
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.